Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3033 in Healthy Participants
NCT07311226Phase 1Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3033 (6 arms), sponsored by Innovent Biologics. Primary endpoint: Incidence of adverse events (AEs)/serious adverse events (SAEs) at Day 85. Started Dec 2025; status: active, not recruiting.
02
Drugs
IBI3033
Beyond the preview
Go deeper on NCT07311226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07311226.